Compare POWI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | CRSP |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.9B |
| IPO Year | 1997 | 2016 |
| Metric | POWI | CRSP |
|---|---|---|
| Price | $87.17 | $53.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 17 |
| Target Price | $60.00 | ★ $70.29 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $443,504,000.00 | $289,590,000.00 |
| Revenue This Year | $8.12 | $807.72 |
| Revenue Next Year | $16.54 | $172.52 |
| P/E Ratio | $1,453.08 | ★ N/A |
| Revenue Growth | 5.86 | ★ 9169.85 |
| 52 Week Low | $30.86 | $44.12 |
| 52 Week High | $89.00 | $78.48 |
| Indicator | POWI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 55.02 |
| Support Level | $44.13 | $51.58 |
| Resistance Level | $89.00 | $59.61 |
| Average True Range (ATR) | 5.24 | 2.81 |
| MACD | -0.08 | 0.15 |
| Stochastic Oscillator | 95.79 | 50.80 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.